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Quantifying circulating cell-free 
DNA in humans
Romain Meddeb1,2,3,4, Zahra Al Amir Dache1,2,3,4, Simon thezenas1,2,3,4,5, 
Amaëlle otandault1,2,3,4, Rita tanos1,2,3,4, Brice pastor1,2,3,4, Cynthia sanchez1,2,3,4, 
Joelle Azzi1,2,3,4, Geoffroy tousch1,2,3,4, Simon Azan1,2,3,4, Caroline Mollevi1,2,3,4,5, 
Antoine Adenis1,2,3,4,6, Safia el Messaoudi1,2,3,4, Philippe Blache1,2,3,4 & Alain R. thierry1,2,3,4
To our knowledge, this is the first comprehensive study on the influence of several pre-analytical and 
demographic parameters that could be a source of variability in the quantification of nuclear and 
mitochondrial circulating DNA (NcirDNA and McirDNA). We report data from a total of 222 subjects, 
104 healthy individuals and 118 metastatic colorectal cancer (mCRC) patients. Approximately 50,000 
and 3,000-fold more mitochondrial than nuclear genome copies were found in the plasma of healthy 
individuals and mCRC patients, respectively. In healthy individuals, NcirDNA concentration was 
statistically influenced by age (p = 0.009) and gender (p = 0.048). Multivariate analysis with logistic 
regression specified that age over 47 years-old was predictive to have higher NcirDNA concentration 
(oR = 2.41; p = 0.033). McirDNA concentration was independent of age and gender in healthy 
individuals. In mCRC patients, NcirDNA and McirDNA levels were independent of age, gender, delay 
between food intake and blood collection, and plasma aspect, either with univariate or multivariate 
analysis. Nonetheless, ad hoc study suggested that menopause and blood collection time might have 
tendency to influence cirDNA quantification. In addition, high significant statistical differences were 
found between mCRC patients and healthy individuals for NcirDNA (p < 0.0001), McirDNA (p < 0.0001) 
and McirDNA/NcirDNA ratio (p < 0.0001). NcirDNA and McirDNA levels do not vary in the same way 
with regards to cancer vs healthy status, pre-analytical and demographic factors.
Since Mandel and Metais discovered the presence of nucleic acids in serum in the 1940s1, different studies have 
reported elevated levels of circulating DNA (cirDNA) in the blood of patients suffering from various diseases2–6, 
especially cancer7–10. Despite scant early consideration, interest in the feasibility of cirDNA analysis has increased 
exponentially, over the last decade, among researchers working on a large range of disorders. CirDNA was first 
clinically implemented in prenatal diagnosis of sex-determination and pregnancy-associated disorders by assay-
ing fetal DNA in maternal plasma11–13. The main sources of cirDNA are cell death, either by necrosis or apop-
tosis, and active release by viable cells, including exocytosis and NETosis14,15. Note, cirDNA may derive from 
either nuclear (NcirDNA) or mitochondrial DNA (McirDNA). To date, research and development of cirDNA 
analysis has focused on the qualitative rather than the quantitative information provided. For example, cirDNA 
analysis is now clinically validated for detecting specific sequences or mutations to guide the oncologist toward 
the most appropriate treatment. CirDNA analysis is also performed for prenatal and embryo-culture genetic 
testing. There have been several years of intensive studies validating cirDNA quantitation in different clinical 
scenarios, including sepsis, transplant recipients and immune disorders. CirDNA quantification is also now 
taken into consideration in oncology as, it was recently shown that, the level of mutant cirDNA is useful for 
following-up cancer patients to detect minimal residual disease and to monitor response to therapy and disease 
recurrence. Although total cirDNA levels were first examined in the early phase of cirDNA research and devel-
opment, it is now not considered as a single biomarker because of its lack of specificity. Nevertheless, all cirDNA 
analysis relies on the optimal quantification of total amount of cirDNA. Biological biomarkers should be highly 
dynamic, and their diagnostic performance may vary depending on internal and external changes. The clinical 
efficacy of cirDNA will require the identification and the control of various patient-related confounders that may 
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affect its measurement16. Human cellular aging is usually marked by senescence and cell death. Similarly, it often 
features a phenomenon, originally called “Inflamm-aging”, that induces a chronic or low-grade inflammatory 
state17–20. Indeed, it was demonstrated that tissue damage and a pro-inflammatory environment increase release 
of cirDNA into the blood stream14. Additionally, we may speculate that sex-based differences, such as genetic 
dissimilarity and steroid hormones levels, could cause differences in cirDNA concentration between men and 
women. Likewise, blood component concentrations may vary with the circadian clock and upon food intake 
and potentially influencing cirDNA concentration21. Despite outstanding research in the field of cirDNA, rela-
tively few studies have examined the effect of pre-analytical and demographic parameters as sources of intra- and 
inter-individual variability in cirDNA levels. There is currently no single operating procedure and there are rela-
tively few clinical guidelines in the literature22–25. This study aims first at defining a framework for cirDNA analy-
sis, to harmonize NcirDNA and McirDNA quantification and to explore potential sources of variability that could 
cause interpretation errors. Previous studies already documented various pre-analytical limitations and specified 
conditions for cirDNA analysis, including specific collection tubes, and specific plasma isolation and extraction 
protocols, including storage condition variables and limits on the number of freeze-thaw cycles22–24,26. Here, we 
study the influence of various pre-analytical (plasma aspect, delay between blood collection and last food intake) 
and demographic variables such age and gender in NcirDNA and McirDNA concentration determination, from 
plasma of 104 healthy donors and 118 mCRC patients (Fig. 1). In addition, we compared McirDNA and NcirDNA 
levels in healthy individuals and mCRC patients. Some others pre-analytical conditions such as blood collection 
tubes, blood collection time and blood stability were examined ad hoc study on healthy volunteers.
Results
Simultaneous quantification of NcirDNA and McirDNA. We used serial dilutions of genomic DNA 
and of mitochondrial plasmid DNA to validate a reproducible, linear and sensitive assay to quantify, both nuclear 
and mitochondrial, circulating DNA (NcirDNA and McirDNA). The NcirDNA assay is based upon the qPCR 
detection of a sequence of the KRAS gene and it can detect one copy of nuclear KRAS gene per 6 microliters of 
plasma (1 nuclear Genome Equivalent per 12 µL). The McirDNA assay can detect down to one copy of the mito-
chondrial MT-CO3 gene per 1.7 microliter of plasma (1 mitochondrial Genome Equivalent per 1.7 µL). Note, 
the targeted MT-CO3 gene sequence was selected as being not mutated in the mitochondrial genome of cancer 
patients. Copy number calculation is performed by using a specific equation that eliminates bias in the nuclear 
or mitochondrial DNA calibration curves to allow simultaneous calculation of their real relative proportions. For 
example, in the cohort of 104 healthy individuals, we found a median NcirDNA and McirDNA plasma concen-
tration of 1.64 × 103 and 8.32 × 107 copies/mL, respectively, corresponding to 5.43 and 1.36 ng/mL of plasma.
Comparison between NcirDNA and McirDNA levels. We compared NcirDNA and McirDNA con-
centration, in healthy individuals and mCRC patients groups, expressed either in copy number/ml and ng/ml of 
plasma. A supplementary table summarizes all quantification data and comparative tests in detail (Supplementary 
Table S1). There was a highly statistical difference between NcirDNA and McirDNA concentration expressed in 
copy number/ml, in healthy individuals (Fig. 2A; Mann-Whitney U test, P value < 0.0001) and equally in mCRC 
patients (Fig. 2B; Mann-Whitney U test, P value < 0.0001). We next compared McirDNA and NcirDNA concen-
tration expressed in ng/ml, in healthy individuals and mCRC patients groups. Here, also, we observed a con-
siderable statistical difference between NcirDNA and McirDNA concentrations in healthy individuals (Fig. 2C; 
Mann-Whitney U test, P value < 0.0001) and mCRC patients (Fig. 2D; Mann-Whitney U test, P value < 0.0001). 
McirDNA concentration is significantly higher than NcirDNA concentration when measured in units of copy 
number/ml, and conversely, the NcirDNA concentration was significantly higher than the McirDNA concentra-
tion when measured in ng/ml, either in healthy individuals and mCRC patients.
Figure 1. Flow chart of the study.
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Effect of age and gender on cirDNA concentrations in healthy individuals. NcirDNA. Age 
(n = 104): We dichotomized the healthy individuals cohort in two groups around the median age, which was 
47 (Table 1). The median NcirDNA copy number in the <47 years-old group (n = 52) and in the ≥47 years-old 
group (n = 52) were 1.36 × 103 and 1.73 × 103 copies/ml, respectively. A statistical difference was found between 
young and older healthy individuals groups (Fig. 3A; Mann-Whitney U test, P value = 0.009).
Gender (n = 104): The median NcirDNA copy number in the healthy male group (n = 62) and in the group 
of healthy females (n = 42) were 1.69 × 103 and 1.48 × 103 copies/ml, respectively. This difference in the NcirDNA 
copy number between healthy males and females was statistically significant (Fig. 3B; Mann-Whitney U test, P 
value = 0.048).
Multivariate analysis: Logistic regression analysis including age and gender specified that age over 47 
years-old was predictive to have higher NcirDNA concentration (Fig. 3C; OR = 2.41, P = 0.033). Results of mul-
tivariate analysis and Odds ratios (OR) with 95% confidence intervals (CIs) are summarized in Supplementary 
Table S2A.
McirDNA. Age (n = 104): The median McirDNA copy number in the <47 (n = 52) and in the ≥47 year-old 
group (n = 52) were 7.77 × 107 and 8.40 × 107 copies/ml, respectively. There was no statistical difference in the 
McirDNA copy number between these groups (Fig. 3D; Mann-Whitney U test, P value = 0.489).
Gender (n = 104): The median McirDNA copy number in the healthy male group (n = 62) and in the group 
of healthy women (n = 42) were 8.03 × 107 and 9.39 × 107 copies/ml, respectively. No statistical difference in 
McirDNA copy number was observed between healthy males and females (Fig. 3E; Mann-Whitney U test, P 
value = 0.485).
Multivariate analysis: Logistic regression analysis including age and gender confirmed no statistically signifi-
cant difference between studied groups (Fig. 3F). Results of multivariate analysis and Odds ratios (OR) with 95% 
confidence intervals (CIs) are summarized in Supplementary Table S2B.
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Figure 2. Respective values of NcirDNA and McirDNA plasma concentration. Boxplot analysis of cirDNA 
concentrations from healthy individuals (N = 104) (A,C) and mCRC patients (N = 50) (B,D). Values are 
expressed either as copy number/ml (A,B) or as ng/ml (C,D). CirDNA concentration was determined as 
described in Materials and Methods. Boxplot represent median with min to max of values and Mann-Whitney 
U test was performed for comparison. A probability of ≤0.05 was considered to be statistically significant; 
*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001.
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Effect of various parameters on cirDNA concentrations in mCRC patients. NcirDNA. Plasma 
aspect (n = 106): We first compared two groups, 27 abnormal plasmas (icteric and/or opaque plasmas) and 79 
normal plasmas. There was no statistical difference in NcirDNA levels between abnormal plasmas and normal 
plasmas groups (Fig. 4A; Mann-Whitney U test; P value = 0.266). However, the median NcirDNA amount deter-
mined in abnormal plasmas group was slightly lower than in normal plasmas (3.62 × 103 vs 5.22 × 103 copies/ml).
Delay between blood collection time and last food intake (n = 89): We then compared two groups, 
“1 h < delay < 5 h” (n = 69) and “other delays” (n = 20). There was no statistical difference in NcirDNA levels 
between “1 h < delay < 5 h” and “other delays” (Fig. 4B; Mann-Whitney U test; P value = 0.220). Nonetheless, the 
“1 h < delay < 5 h” group showed lower median NcirDNA amount than the group “other delays” (3.68 × 103 vs 
5.72 × 103 copies/ml).
Age (n = 118): We also dichotomized the mCRC cohort into two groups around the median age of 65 
(Table 1). The median NcirDNA copy number in the <65 year-old group (n = 52) and in the ≥65 year-old group 
(n = 66) were 4.73 × 103 and 4.94 × 103 copies/ml, respectively. No statistical difference was found (Fig. 4C; 
Mann-Whitney U test, P value = 0.757). A comparative study using the same cut-off for both healthy and mCRC 
cohorts as the median age of all individuals tested here (N = 222, median age = 56 years) confirmed the statisti-
cal difference between young (N = 79) and older (N = 25) healthy individuals groups (Mann-Whitney U test, P 
value = 0.0026), and also the no statistical difference between young (N = 25) and older (N = 93) mCRC groups 
(Mann-Whitney U test, P value = 0.913) (Supplementary Fig. S1A,B).
Gender (n = 118): The median NcirDNA copy number in the mCRC males (n = 68) and in and females 
(n = 50) mCRC patients were 4.65 × 103 and 5.40 × 103 copies/ml, respectively. No statistical difference was found 
(Fig. 4D; Mann-Whitney U test, P value = 0.971).
Multivariate analysis: Logistic regression analysis including all the parameters (plasma aspect, delay, age and 
gender) confirmed no statistical significant results (Fig. 4E). Results of multivariate analysis and Odds ratios (OR) 
with 95% confidence intervals (CIs) are summarized in Supplementary Table S2C.
McirDNA. Plasma aspect (n = 46): We next compared the abnormal plasmas (n = 11) and normal plasmas 
(n = 35) groups. There was no statistical difference in NcirDNA levels between abnormal and normal plasmas 
groups (Fig. 5A; Mann-Whitney U test; P value = 0.263). However, the median McirDNA amount determined in 
abnormal plasmas was slightly lower than in normal plasmas (6.64 × 106 vs 1.19 × 107 copies/ml).
Delay between day-time of blood draw and the last food intake (n = 34): There was no statistical difference 
in McirDNA copy number between the “1 h < delay < 5 h” group (n = 25) and the “other delay” group (n = 9) 
(Fig. 5B; Mann-Whitney U test; P value = 0.509). The “1 h < delay < 5 h” group showed higher median NcirDNA 
amount than the group “other delay” (1.68 × 107 vs 1.19 × 107 copies/ml).
Age (n = 50): The median McirDNA copy number in the < 65 year-old (n = 23) and ≥ 65 year-old (n = 27) 
groups were 1.12 × 107 and 1.84 × 107 copies/ml, respectively. There was no statistical difference in the McirDNA 
copy number between the groups (Fig. 5C; Mann-Whitney U test, P value = 0.240).
Gender (n = 50): The median McirDNA copy number in the mCRC males group (n = 25) and in the group of 
mCRC women (n = 25) were 1.19 × 107 and 1.68 × 107 copies/ml, respectively. We did not found any statistical 
difference in the McirDNA copy number between mCRC males and females (Fig. 5D; Mann-Whitney U test, P 
value = 0.261).
Multivariate analysis: Logistic regression analysis including all the parameters (plasma aspect, delay, age and 
gender) confirmed no statistically significant results (Fig. 5E). Results of multivariate analysis and Odds ratios 
(OR) with 95% confidence intervals (CIs) are summarized in Supplementary Table S2D.
Patient’s characteristics
Healthy individuals (N = 104) mCRC patients (N = 118)
Age (years)
Mean 45 Mean 65
Median 47 Median 65
(min-max) (18–69) (min-max) (22–91)
Gender
Males 62 59,6% Males 68 57,6%
Females 42 40,4% Females 50 42,4%
TOTAL 99 TOTAL 118
Males (N)
Mean age 45 Mean age 65
Median age 47 Median age 65
(min-max) (19–69) (min-max) (34–88)
Females (N)
Mean age 44 Mean age 65
Median age 45 Median age 67
(min-max) (18–63) (min-max) (22–91)
Table 1. Characteristics of healthy individuals (N = 104) and mCRC patients (N = 118).
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Comparing cirDNA levels between mCRC patients and healthy individuals. NcirDNA. We com-
pared the median NcirDNA amount between healthy individuals (n = 104) and mCRC patients (n = 118). The 
median NcirDNA concentration in healthy individuals and mCRC patients was 1.64 × 103 and 4.73 × 103 cop-
ies/ml, respectively, revealing a significant difference between healthy individuals and mCRC patients (Fig. 6A; 
Mann-Whitney U test, P value < 0.0001).
Figure 3. Influence of age and gender on cirDNA concentration in healthy individuals. Boxplot analysis of 
cirDNA concentration extracted from healthy individuals (N = 104), with regards to age (A,D) and gender 
(B,E). (C,F) Multivariate analysis representations. NcirDNA (A–C) and McirDNA (D–F) concentrations are 
expressed in copy number/ml of plasma. Boxplot represent median with min to max of values. Mann-Whitney 
U test was performed for univariate analysis and logistic regression was performed for multivariate analysis. 
Odds ratio (OR) with 95% confidence intervals (CIs) are represented. A probability of ≤0.05 was considered to 
be statistically significant; *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001.
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McirDNA. Next we compared the median McirDNA amount between healthy individuals (n = 104) and mCRC 
group (n = 50). The median McirDNA concentration in healthy individuals and mCRC patients was statistically 
different at 8.32 × 107 and 1.44 × 107 copies/ml, respectively (Fig. 6B; Mann-Whitney U test, P value < 0.0001).
McirDNA/NcirDNA ratio. Finally we compared the median McirDNA/NcirDNA ratio between healthy indi-
viduals (n = 104) and mCRC patients (n = 50). The median McirDNA/NcirDNA ratio in healthy individuals 
Figure 4. Influence of various factors on NcirDNA concentration in mCRC patients. Boxplot analysis 
of NcirDNA concentration extracted from mCRC patients (N = 118), with regards to plasma aspect (A); 
delay between blood collection and last food intake (B); age (C) and gender (D). (E) Multivariate analysis 
representation. Boxplot represent median with min to max of values. Mann-Whitney U test was performed for 
univariate analysis and logistic regression was performed for multivariate analysis. Odds ratio (OR) with 95% 
confidence intervals (CIs) are presented. A probability of ≤0.05 was considered to be statistically significant; 
*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001.
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and mCRC patients were statistically different at 5.41 × 104 and 2.70 × 103 copies/ml, respectively (Fig. 6C; 
Mann-Whitney U test, P value < 0.0001). The median McirDNA/NcirDNA ratio was 20-fold higher in the healthy 
individuals group than in the mCRC patients group. We did the same comparison using McirDNA and NcirDNA 
concentrations expressed in ng/ml and we obtained the same results (Supplementary Fig. S2, Mann-Whitney U 
test, P value < 0.0001).
Figure 5. Influence of various factors on McirDNA concentration in mCRC patients. Boxplot analysis 
of McirDNA concentration extracted from mCRC patients (N = 50), with regards to plasma aspect (A); 
delay between blood collection and last food intake (B); age (C) and gender (D). (E) Multivariate analysis 
representation. Boxplot represent median with min to max of values. Mann-Whitney U test was performed for 
univariate analysis and logistic regression was performed for multivariate analysis. Odds ratio (OR) with 95% 
confidence intervals (CIs) are presented. A probability of ≤0.05 was considered to be statistically significant; 
*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001.
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CirDNA stability in whole blood samples of healthy volunteers. NcirDNA concentration in blood 
collected in EDTA tubes increased by more than two-fold and three-fold respectively, at days 2 and 5 after blood 
collection (Supplementary Fig. S3A). In contrast, there was no difference between days 0, 2, 5 and 7 following 
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Figure 6. Biomarker capacity of respective NcirDNA and McirDNA concentration for discriminating healthy 
individuals and mCRC patients. The cohort was dichotomized in two populations (mCRC patients and healthy 
individuals). Boxplot analysis of the amount of NcirDNA (A) and McirDNA (B) extracted from plasma of all 
individuals (N = 222 and N = 154, respectively). (C) Boxplot analysis of the McirDNA/NcirDNA ratio of all 
individuals (N = 154). The boxplots represent medians with min to max of values and Mann-Whitney U test 
was performed for comparison. A probability of ≤0.05 was considered to be statistically significant; *p ≤ 0.05, 
**p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001.
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blood collection in Cell-Free DNA BCT® STRECK (BCT) tubes (Supplementary Fig. S3B). Note, median values 
at day 0 are similar in plasma from blood collected in EDTA or BCT tubes. In addition, The McirDNA concen-
tration in blood collected in EDTA tubes approximately increased more than 12-fold and 27-fold respectively, at 
days 2 and 5 after blood collection (Supplementary Fig. S3C).
Effect of the blood collection time on cirDNA levels in healthy volunteers. NcirDNA. In EDTA 
tubes at 9.00 AM (fasted state), 12.00 PM (2 hours after breakfast), 3.00 PM (2 hours after lunch) and 6.00 PM, 
the median NcirDNA copy numbers were 1500, 480, 715 and 709 copies/ml respectively. An additional figure 
shows this in more detail (Supplementary Fig. S4A,E). Taking the four healthy individuals together, the median 
NcirDNA concentration strongly changed from the fasted state to three hours after breakfast. Median NcirDNA 
concentration was slightly higher at the earliest collection time in BCT tubes, over the same time-course 
of the day, at 874, 562, 728 and 313 copies/ml, respectively. An additional figure shows this in more detail 
(Supplementary Fig. S4B,F). Altogether our data from both collection methods showed that NcirDNA content 
in healthy individuals declined from 9.00 AM to 12.00 PM then plateaued up to the 6.00 PM collection time. An 
additional figure shows this in more detail (Supplementary Fig. S4C,D,G,H).
McirDNA. In EDTA tubes from healthy individuals, the median NcirDNA copy numbers were unchanged over 
the time course at 1.05, 1.25, 1.17 and 1.26 million copies/ml. An additional figure shows this in more detail 
(Supplementary Fig. S5A,B). No clear difference was found when comparing McirDNA amounts collected at 
the various collection time points. Note, plasma appearance become opaque at 6.00 PM. An additional picture 
illustrates this observation (Supplementary Fig. S6).
Discussion
Here, we present a comprehensive study on the quantification of nuclear and mitochondrial cirDNA in the plasma 
of healthy individuals and a homogenous cohort of mCRC patients. To our knowledge, this work is the first to 
address altogether the influence of various preanalytical, analytical and demographical factors on NcirDNA and 
McirDNA levels in a large set of individuals (n > 200). Solid tumor mass is composed of a variety of cells, mostly 
consisting of malignant/cancer, stromal, endothelial and immunological cells. In order to avoid any confusion in 
nomenclature, we define as ‘tumor cells’ all the cells composing the tumor mass. The concentration values pre-
sented in this study correspond to total cell-free DNA in plasma, either of nuclear or mitochondrial origin. Our 
observations are summarized in Table 2 and Supplementary Table S3.
total cirDNA levels. This study design relies on the analytical performance of the assay. We used here a 
qPCR-based method with an unmatched combination, of reproducibility, sensitivity and specificity for quan-
tifying plasma cirDNA (see Methods section). Furthermore, our assay benefits from a clinically-validated opti-
mal pre-analytic process that we previously set up for plasma preparation22; and adapted from Chiu et al., DNA 
extraction and sample handling27. The accuracy of the cirDNA concentration measurement in this study is sup-
ported by two assessments: (i) total cirDNA concentration by targeting a KRAS sequence was routinely controlled 
by quantifying a BRAF sequence. In addition, this control quality enable to detect and exclude sample with loss of 
heterozygosity (LOH) or gene amplification which have been reported in CRC patients28. Moreover, since KRAS 
amplification is an infrequent event in CRC (0.67%)28, this level will not modify our observations or the values 
described in our manuscript; and (ii) the study of cirDNA measurement under Poisson law distribution revealed 
single copy detection of nuclear cirDNA.
Respective NcirDNA and McirDNA proportions inverted when the plasma cirDNA concentrations were cal-
culated according to copy number or mass (Fig. 2A,C). For example, data obtained from 104 healthy individu-
als revealed that median McirDNA plasma concentration was approximately 50,000-fold higher than median 
NcirDNA plasma concentration in terms of copy number/mL (99.998% McirDNA and 0.002% NcirDNA), cor-
responding to approximately 4-fold lower in terms of ng/ml (25.0% McirDNA and 75.0% NcirDNA). This high-
lights the much lower size of the mitochondrial genome (16569 bp) than the nuclear genome (about 3 × 109 bp), 
and also the high number of mitochondrial genome copies within a cell. Each human cell, depending on its type, 
contains a number of mitochondria ranging from 500 to 2,000 and each mitochondria holds between 2 and 10 
mitochondrial DNA molecules. Therefore, each cell may contain approximatively 1,000 to 20,000 mitochondrial 
DNA molecules and only one nuclear genome equivalent, which is consistent with our results. Our method of 
calculation, described here, appears as the most rigorous means to simultaneously quantify mitochondrial and 
nuclear DNA concentrations. A higher coefficient of variation was routinely observed for mitochondrial than for 
nuclear DNA, despite the higher analytical signal for McirDNA copy number. The median concentration levels 
we found here appear to be similar to the average values observed in several studies27,29. In addition, performance 
of our assay support the accuracy of the values presented throughout this study such as 5.43 and 1.36 ng/mL in 
healthy subject plasma of N- and McirDNA, respectively. Considering the significant percentage of McirDNA 
(i.e.: 25% in healthy subjects) among total cirDNA mass existing in plasma, we propose to always specify the 
origin of cirDNA when examining total circulating WT DNA.
Influence of age and gender on NcirDNA levels in healthy individual plasma. Most studies found 
no relationship between NcirDNA levels and any demographic parameters, such as age and gender, in healthy 
individuals30–32. A few studies showed opposite observations33–35. Here, we observed an influence of age on 
NcirDNA plasma concentration in the healthy individual cohort as a whole (p = 0.009). Our data also revealed a 
statistical difference in NcirDNA amount between healthy males and females (p = 0.048). We performed logistic 
regression for multivariate analysis including age and gender and showed that age ≥ 47 was predictive of a high 
NcirDNA concentration (OR = 2.41, p = 0.033). This observation is in accordance with a study by Jylhävä et al. 
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that consisted of 12 nonagenarian women (age > 90 years) and 11 healthy control female (22 < age < 37 years) 
that showed a higher concentration of NcirDNA in nonagenarians than in control women33. The authors 
explained this increase in the amount of cirDNA with age, as the accentuation of a senescence phenomenon and 
cell death, caused by an inflammation associated with age and even by decreased clearance and phagocytic capac-
ity. Zhong et al. showed a significant increase in total plasma cirDNA concentration in women over 60, compared 
to younger women, which appears to be consistent with Jylhävä’s study. We may speculate that menopause could 
be an explanation of the statistically higher NcirDNA concentration in healthy males as compared to healthy 
females (p = 0.048), whereas no difference between mCRC males and females was observed (p = 0.971). This 
speculation is based on two observations: (i) Median menopausal age in the European population is 51 years-old; 
10–15% of women go into menopause before the age of 45, and globally 90–95% reach menopause by 55 years 
of age. By applying these categories of age to our women cohorts, we observed no statistical difference and no 
tendency between mCRC women <45, 45–54 and ≥55 year-old (Kruskal-Wallis rank test, P value = 0.592) while 
we showed a statistical difference between healthy women <45, 45–54 and ≥55 year-old, with a concentration 
gradient: 1275, 1440 and 2610 median copy number, respectively (Kruskal-Wallis rank test, P value = 0.026); and 
(ii) CRC females are at a high risk of chemotherapy-induced menopause or menstrual disorders like amenorrhea 
or a decrease of steroid hormone levels36,37, and metachronous mCRC patients may attain a menopausal state 
earlier. An additional figure shows these results in more detail (Supplementary Fig. S7).
Influence of various parameters on NcirDNA levels in mCRC patients plasma. Despite the large 
number of studies that aimed at determining if age and gender might influence NcirDNA levels, no clear results 
have been demonstrated30–32,38. There are discrepancies in the literature with regards to the influence of age and 
gender in patient populations suffering from various types of cancers. These discrepancies could result from 
use of serum, or pre-analytical or analytical factors. Note, a study by Hohaus et al. showed that patients with 
Hodgkin and non-Hodgkin’s lymphoma over 60 year-old (n = 142) had higher levels of cirDNA in plasma than 
younger patients (p = 0.018)38. Conversely, our data showed no statistical influence of age (p = 0.757) and gender 
(p = 0.971) on NcirDNA concentration in mCRC patients and these results was confirmed with a multivariate 
analysis using logistic regression. We also demonstrated no influence of pre-analytical factors like plasma aspect 
(p = 0.266) or delay between last food intake and blood collection (p = 0.220). On the other hand, our results also 
confirm those previously published by our laboratory25 and by many teams39,40, namely that NcirDNA concentra-
tion is significantly higher cancer patients than in healthy individuals (p < 0.0001), whether male or female. For 
more than a decade it was suggested that total NcirDNA could be a cancer biomarker25,41,42. However, previous 
attempts to apply total cirDNA quantity as a screening test for cancer lacked a strong statistical demonstration43. 
High standards, with regard to pre-analytical factors and quantification, could lead to its use as one marker, 
among other, for tumor burden.
McirDNA levels in plasma. Relatively few reports have quantitatively analyzed McirDNA and there are dis-
crepancies among them. In one study there was no significant difference between young and aged healthy subjects35. 
For Pinti et al. however, McirDNA concentration would increase with age18. In this study, McirDNA content was 
analyzed in 831 plasma samples from subjects with different healthy status, aged from 1 to 104 years; McirDNA con-
tent significantly increased after fifty years-of-age and it peaked in nonagenarians. Elevated McirDNA levels might 
Demographical considerations Group N
In accordance with 
previous works
NcirDNA concentration
A statistical difference between males and females Healthy 104 Catarino R, et al.63
No statistical difference between males and females mCRC 118 Hao TB, et al.31
A statistical difference with regard to age Healthy 104 Jylhävä J, et al.35
No statistical difference with regard to age mCRC 118 Van der Drift MA, et al.30
Statistical increase in mCRC patients as compared to healthy individuals HealthymCRC
104
118 Bedin C, et al.
64
McirDNA concentration
No statistical difference between males and females HealthymCRC
104
50 New observation
No statistical difference with regard to age HealthymCRC
104
50
Jylhävä J, et al.35
New observation
Statistical decrease in mCRC patients as compared to healthy individuals HealthymCRC
104
50 New observation
McirDNA vs NcirDNA concentration
Necessity of independently quantifying NcirDNA and McirDNA
About 50,000-fold more McirDNA copy number as compared to 
NcirDNA in healthy individuals Healthy 104 New observation
About 3,000-fold more McirDNA copy number as compared to NcirDNA 
in cancer patients mCRC 50 New observation
About 20-fold more McirDNA/NcirDNA ratio in healthy individuals as 
compared to mCRC patients
Healthy
mCRC
104
50 New observation
Table 2. Summary of the observations made on the influence of demographical factors.
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help maintain the low-grade chronic inflammation that is common in elderly individuals. With regards to McirDNA 
level in cancer patients, Mengel-From et al. measured McirDNA copy number in blood cells from 1,067 subjects 
aged 18 to 93 and conversely, observed a tendency for lower mitochondrial DNA copy number with advanced age44. 
These findings are consistent with other studies, performed on different types of tissue, such as skeletal muscle and 
pancreatic islets45,46. This age-related tissue-specific depletion of cellular mitochondrial DNA could lead to a propor-
tional reduction of McirDNA copy-number in plasma. Inversely, there was no association between serum McirDNA 
levels and demographic parameters (age/gender) in urological malignancies47,48. Likewise, in breast cancer, there was 
no significant difference in McirDNA content in blood samples of stage I patients with respect to their age49. Our 
data revealed no influence of age and gender on McirDNA concentration, either in plasma of healthy individuals or 
mCRC patients. These results were confirmed in multivariate analysis. We also reported no significant influence of 
plasma aspect (p = 0.263) and delay between last food intake and blood collection (p = 0.509). Nonetheless, our data 
revealed a significant higher McirDNA than NcirDNA concentration in plasma, whether for mCRC patients, healthy 
individuals, male or female, and regardless of the age of the subject. Note, while median NcirDNA concentration is 
much higher in mCRC patients than in healthy individuals, median McirDNA concentration is conversely lower in 
mCRC patients, revealing a proportionally lower McirDNA release from cancer cells. This might be explained by 
the fact that cancer cells, in comparison to healthy cells, may have, among other differences, fewer mitochondria per 
cell and less DNA within their mitochondria34,50. However, this is still controversial and explanation of our striking 
observation is under active investigation in our team. Nevertheless, we may speculate that the McirDNA/NcirDNA 
ratio might have some power in discriminating healthy individuals from cancer patients. McirDNA/NcirDNA ratio 
is undergoing clinical validation as potential biomarker for tumor burden or diagnosis in a large study involving 
broader scope of cancer patients with various malignancies and stages. In light of the high copy number of McirDNA 
and its tendency to be mutated in cancer51, our observations confirm the gradual acceptance of McirDNA as a new 
potent diagnostic and prognostic biomarker for many solid tumors52.
Blood stability for cirDNA plasma assessment. As previously reported23,53, NcirDNA concentra-
tion determined from blood collected in EDTA tubes increased with time highlighting release of genomic DNA 
resulting from blood cell lysis when stored at room temperature or +4 °C and consequently to contamination of 
cell-derived DNA. Note, whole blood stored in EDTA tubes at +4 C° showed no change in cirDNA concentration 
for up to one day suggesting their potential use within this time period (data not shown)23,53. We propose routine 
clinical analyses use plasma stored in EDTA tubes for up to 6 hours, given the uncertainty of maintaining the tem-
perature of samples in the course of blood processing, as we earlier described54. Conversely, BCT tubes appeared to 
conserve blood cell integrity, since no DNA concentration increase was observed up to 7 days following blood col-
lection23,55. Thus, BCT tubes maintain the true cirDNA concentration and are good tools to conserve/stabilize blood 
for optimal quantification of NcirDNA for up to 7 days following collection. Cell-preserving tubes greatly allows 
postal shipment of whole-blood within this time period and it allows interventional analysis as well as enabling clin-
ical centers that lack lab facilities to immediately prepare plasma. While being cheaper by themselves, use of EDTA 
tubes necessitates plasma preparation within a short time frame and immediate subsequent storage under frozen 
conditions until analysis requiring costly shipment when plasma originate from a single patient. We first reported 
that McirDNA concentration determined from blood collected in EDTA tubes strongly increased with time. We 
may assume that this results as well blood cell lysis and blood cell-derived mitochondrial DNA contamination.
Effect of blood collection time on cirDNA plasma concentration. There is currently no indication 
in the literature on the optimal time for blood collection when analyzing cirDNA. Our data seem to indicate that 
NcirDNA median levels are 2- to 3-fold higher at 9.00 AM, which is the earliest time-point examined, compared 
to later blood-collection time-points (12.00, 3.00 and 6.00 PM) when the NcirDNA level stabilizes. Decrease from 
9.00 AM to 12.00 PM might be explained by the postprandial effect of the breakfast being taken at 10.00 AM. This 
hypothesis is supported by several observations. First, we reported that NcirDNA plasma levels in blood collected 
between one and five hours after food intake were lower than in blood collected on patients under fasting condi-
tions. It was previously showed that plasma triglyceride increased one hour after food intake, peaked ≈3 hours 
after intake of a test meal and baseline values were restored back to initial values after 5 hours56. Second, NcirDNA 
concentration was lower in opaque than in non-opaque plasmas. Multivariate analysis including age, gender, 
plasma aspect and delay between food intake and blood collection revealed no statistical influence but abnormal 
plasma aspect showed a clear tendency to have lower NcirDNA concentration (OR = 0.399; p = 0.089). These 
observations are all consistent with postprandial effects. Food intake with high lipid content may result in hyper-
lipidemia which can be characterized by opaque plasma and high triglyceride concentrations. However, despite 
the large examined cohort data, we cannot state that postprandial is the explanation since no statistical difference 
was found. This may be due to various factors: (i) blood triglyceride levels largely depend on fat distribution and 
body weight, lifestyle choices, and also genetic factors57; (ii) there were considerable within- and between-subject 
variations in non-fasting plasma triglycerides58; and (iii) the subjects had a chronic illness, mCRC. We specu-
late that the postprandial effect could occur because the presence of lipids or proteins may interfere with DNA 
extraction yield from plasma. We cannot exclude the possibility that NcirDNA levels depend on circadian clocks 
and metabolism, resulting in more elevated concentration in the morning. Moreover, we cannot exclude the 
possibility that other metabolic changes during fasting/feeding alter cirDNA yield. Nevertheless, our data suggest 
that fasting blood samples should be included when studying or clinically examining cirDNA to improve its diag-
nostic performance, especially when low mutation frequency in cancer patients or prenatal testing is considered. 
Note, in addition to opaque plasma, we remarked on various occasions that, icteric plasma had aberrant cirDNA 
concentration when qPCR was the analytical method. Therefore, we propose observation of icteric, hemolytic and 
opaque plasma as criteria of blood sample exclusion.
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Limitations of the study. While the study was carried out with statistically sufficient number of subjects 
to support the observations, the ad hoc study is limited by the low number of tested individuals since ad hoc 
study experiments are cumbersome and time-consuming. Thus, blood stability and blood collection time was 
only carried out on a few number of healthy volunteers (n = 5) and not on mCRC patients. This not allowed us 
to provide statistical analysis while the results showed clear tendencies. A specific study should be performed to 
statistically confirm these results on a larger cohort of healthy volunteers as well as mCRC patients. Although we 
routinely experienced that abnormal plasmas resulted in lowering cirDNA concentration values, we cannot fully 
discriminate the implication of postprandial effects like triglycerides serum level, to the possible involvement of 
biological changes dues to the circadian rhythm. In order to definitively address this issue, it would be interesting 
to compare NcirDNA levels at 9.00 AM and 12.00 AM, with and without breakfast, in order to determine the 
impact of food intake and circadian rhythm, respectively. In addition, the influence of the menopause on cirDNA 
concentration with regard to our observations of gender, age and pathological status is only speculative. A spe-
cific study on the difference of NcirDNA concentration between postmenopausal and premenopausal healthy 
females, as well as the difference between premenstrual and postmenstrual young women, should be performed 
to definitively address this issue. Conclusions drawn here in respect to cancer plasma samples should be restricted 
to mCRC patients and extension to other malignancies or even to localized disease is speculative.
In conclusion, the levels of mitochondrial and nuclear circulating DNA differently vary with regards to 
pre-analytical and demographic factors. Those variables should be taken into consideration when evaluating 
cirDNA analysis in clinical setting and perhaps in the future clinical practice when cirDNA quantification is 
directly or indirectly used as a biomarker. In addition, our study highlights the potential for combining the analy-
sis of NcirDNA and McirDNA since examining their respective levels may have diagnostic value.
Methods
patients. Blood samples collected from 104 healthy donors were provided by the Etablissement Français du 
Sang (E.F.S), the blood transfusion center of Montpellier (Convention EFS-PM N° 21PLER2015-0013). Blood 
samples collected by the E.F.S were analyzed (virology, serology, immunology, blood numeration). If an anomaly 
is detected, the sample is ruled out and the donor is warned then by mail. NcirDNA concentration and McirDNA 
copy number were determined for all healthy individuals. Data on age and gender were collected for all healthy 
individuals. mCRC patients data are taken from a study comparing the detection of KRAS exon 2 and BRAF 
V600E mutations by circulating DNA (cirDNA) analysis to conventional detection by tumor tissue analysis59. This 
study (KPLEX2) was performed and presented under the STARD criteria. 140 patients have been included in 11 
clinical centers in France, over a period of 12 months. Eligible patients were male or female, aged ≥18 years, with 
a proven histologically mCRC, a measurable disease as defined by response evaluation criteria in solid tumors 
(RECIST v1.1) and untreated by radiotherapy or chemotherapy in the last 4 weeks before inclusion. There is no 
possibility that cirDNA from mCRC patients can be affected by therapy since eligible patients were untreated by 
radiotherapy or chemotherapy in the last 4 weeks before blood collection (inclusion criteria). Written consent 
was obtained from the part of all patients. Inclusion criteria were described previously59. 19 were excluded from 
analysis for no respect of the inclusion criteria (due to various inclusion criteria) and 3 were excluded due to lack 
of data collected on age or gender. NcirDNA analysis was performed on 118 patients and McirDNA analysis on 
50/118 mCRC patients. While study on age and gender effect were carried out on all the included mCRC patients 
for NcirDNA (N = 118), cohort patient number varied when studying plasma aspect and delay for NcirDNA, 
or age and gender for McirDNA because of two main reasons: non-reported information for delay and plasma 
aspect for to NcirDNA and insufficient plasma volume needed to carry out supplementary analysis for McirDNA. 
All data on age and gender were collected. Plasma aspect (normal, abnormal: opaque or/and icteric) was noted for 
106/118 mCRC patients and delay between time of blood draw and the last food intake was informed for 89/118 
mCRC patients.
Ethics approval and consent to participate. Blood samples collected from 104 healthy donors were 
provided by the Etablissement Français du Sang (E.F.S), the blood transfusion center of Montpellier (Convention 
EFS-PM N° 21PLER2015-0013). Plasma samples from mCRC patients were obtained from the Kplex2 study 
registration number EUDRACT 2016-001490-33 with ethic committee approval (“Comité de Protection des 
Personnes”, Nimes, France). All methods were performed in accordance with the relevant guidelines and regula-
tions. The study obtained informed consent from all participants for the study.
Blood stability. 7 samples for each healthy donor were collected at 9.00 a.m. on Day 0 (fasted state): 3 with 
EDTA K2 tubes and 4 with Cell-Free DNA BCT® STRECK tubes. Each tube was processed as we early described, 
at day 0, 2 and 5 for EDTA tubes and day 0, 2, 5 and 7 for BCT tubes. EDTA tubes were stored at +4 °C and BCT 
tubes were conserved at room temperature before isolation. Healthy individual N°1 (HI1) and N°2 (HI2) are 57 
year-old and 29 year-old men, respectively, both with no known disease. Healthy individual N°3 (HI3), N°4 (HI4) 
and N°5 (HI5) are 25 year-old, 24 year-old and 28 year-old women, respectively, both with no known diseases. 
NcirDNA analysis for HI1 was not performed due to clotting in BCT tubes.
Blood collection time. 4 blood collection times were defined 9.00 a.m. (fasted state), 12.00 p.m. (2 hours 
after breakfast), 3.00 p.m. (2 hours after lunch) and 6.00 p.m. (4 hours after lunch). One EDTA K2 and one 
Cell-Free DNA BCT® STRECK tube per day-time were collected for each donor. Healthy individual N°6 (HI6) 
and N°7 (HI7) are 29 year-old and 27 year-old men, respectively, both with no known diseases. Healthy individual 
N°8 (HI8) and N°9 (HI9) are 28 year-old and 30 year-old women respectively, both with no known diseases. Each 
donors took the same meal during breakfast: one butter croissant, one chocolate croissant and one coffee with 
sugar; and for the lunch: a dish of tomato rice with sausage, bread and one coffee with sugar.
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Sample characteristics and preparation. Samples were collected and treated in accordance with a 
pre-analytical guideline previously established by our group22. In summary, blood was collected in EDTA K3 
tubes and plasma was isolated within 2 hours. The isolation technique consist of a double centrifugation. Initially, 
tubes were centrifuged for 10 minutes at 4 °C and 1,200 g in a Heraeus Multifuge LR centrifuge. The supernatant 
was collected while carefully avoiding the buffy-coat. The second centrifugation was conducted for 10 minutes at 
4 °C and 16,000 g. The supernatant was transferred to 1.5 ml tubes before performing the extraction of cirDNA or 
being stored at −20 °C. CirDNA extraction was performed with the Qiagen Blood Mini kit, following all steps of 
the protocol. In all, 0.2 to 1 ml of plasma was extracted in several successive passes on a column. The final elution 
volume was 80 to 130 µl and eluates were frozen at −20 °C prior to analysis by qPCR. Freeze-thaw cycles should be 
avoided to reduce the phenomenon of cirDNA fragmentation and the extracts are not kept longer than 3 months 
at −20 °C.
Q-PCR analysis. CirDNA analysis was performed by a qPCR technique developed in our laboratory, and clin-
ically validated previously60. The method is based on an innovative design of short amplicons (60–100 bp ± 10 bp) 
targeting a wild-type sequence of the gene, (here the KRAS nuclear gene and the mitochondrial Cytochrome oxi-
dase III gene, MT-CO3). Quantification of this amplicon gives an estimation of the total NcirDNA and McirDNA 
concentration, respectively. For the quantification of NcirDNA, we amplified of a 67 bp-length sequence of 
the KRAS gene with the following primers: forward (5′ CCTTGGGTTTCAAGTTATATG 3′) and reverse (5′ 
CCCTGACATACTCCCAAGGA 3′). For McirDNA, we amplified a 67 bp-length sequence of the cytochrome 
oxidase sub-unit 3 mitochondrial gene with the following primers: forward (5′ GACCCACCAATCACATGC 
3′) and reverse (5′ TGAGAGGGCCCCTGTTAG 3′). These primers were designed using the Primer 3 software 
according to the following requirements: (i) Tm ranging from 50 to 64 °C; (ii) GC-content between 40 and 60%; 
(iii) size from 18 to 23 NT; (iv) amplicon size ranging from 60 to 100 bp. We performed local-alignment analyses 
with the BLAST program to confirm the specificity of the designed primers. All sequences were checked for self- 
or inter-molecular annealing with nucleic-acid-folding software (Mfold and oligoAnalyzer 1.2). Oligonucleotides 
were synthesized and HPLC-purified by Eurofins (Ebersberg, Germany) and quality control of the oligonucleo-
tides was performed by MALDI-TOF. For all analyses, negative controls and standard curves were used. All tests 
are performed in triplicate with 5 µl of DNA extract in a 25 µl reaction volume, on a CFX96 instrument using CFX 
manager software (Bio-Rad). This method (qPCR, primer design, program) and technical validation have been 
described previously25. The mCRC patient’s blood samples were excluded if the total cirDNA concentration, due 
to a problem of pre-analytic treatment or even for unknown reasons, was below a quality threshold.
The DNA concentration quality threshold was 3 ng/mL (about 900 copies/mL) for cancer patients. Note, this 
value corresponds to about the half of the median concentration found for healthy individuals (N = 104, median 
NcirDNA concentration = 5.43 ng/mL of plasma corresponding to 1645 copies/mL). In addition to quantifying 
cirDNA by targeting two different sequences on two different chromosomes, an experiment based on Poisson 
law distribution showed the accuracy of our cirDNA amount measurement (Supplementary Fig. S8). It should 
be noted that our Q-PCR systems enable the detection of a single genome copy (Supplementary Table S4), and 
that we have previously shown that targeting a DNA sequence of the same size or longer than the input DNA 
fragment produced a similar PCR yield61. The measurement of the total cirDNA concentration by targeting a 
KRAS sequence was routinely controlled by quantifying a BRAF sequence. Control quality is acceptable when the 
KRAS-based value is 1.3 to 1.8-fold higher than that of the BRAF-based value when using the reported Q-PCR 
primer systems; otherwise, a second analysis is performed. Note, BRAF analysis data from 33 healthy individ-
uals were not available. In addition, we excluded 26 patient plasmas (17 mCRC and 9 healthy) in which the 
KRAS/BRAF ratio was over 3 or below 0.5. Data revealed that the KRAS-based concentration value was posi-
tively correlated with the BRAF-based concentration values in the 62 healthy individuals (Spearman analysis; 
r = 0.762, P value < 0.0001) and in the 101 mCRC patients (Spearman analysis; r = 0.882, P value < 0.0001) 
(Supplementary Fig. S9). We already addressed this issue in our previous report (Spearman analysis; r = 0.966, 
P value < 0.001)25.The KRAS and BRAF genes are monogenic and poorly amplified in both healthy and cancer 
individuals62. Supplementary section figures present NcirDNA concentration determined from targeting BRAF 
with using a primer set of similar size. Data revealed that the same observations could be made: the NcirDNA 
amount, as determined using BRAF sequence targeting, is statistically different in healthy (N = 62) and mCRC 
individuals (N = 101) (Supplementary Fig. S10; Mann-Whitney U test, P value < 0.0001), and fully correlates with 
our observation based on KRAS sequence targeting. We may therefore indicate that amplification of the KRAS 
gene will not have any influence on the observations and conclusions made in this study. Valtorta et al. detected 
KRAS amplification in 7/1,039 (0.67%) evaluable CRC specimens, demonstrating that KRAS amplification is an 
infrequent event in CRC28. Thus this level will not modify significantly the observations or values described in 
our manuscript.
CirDNA calibration assay. NcirDNA. A genomic DNA extract from human wild-type KRAS colorectal 
cells was used for the NcirDNA calibration assay. Initial genomic DNA solution concentration and purity were 
determined by measuring optic density at λ = 260 nm, 230 nm and 280 nm, with an Eppendorf BioPhotometer® 
D30. Starting genomic DNA concentration was adjusted to 1800 pg/µl for the first dilution point, according to 
optic density measurement at λ = 260 nm. A qPCR standard curve was obtained by 6 successive dilutions of the 
vector solution (1800, 180, 45, 20, 10 and 5 pg/µl). The standard curve was used to determine the NcirDNA con-
centration of the mCRC patients and healthy individuals and calculate the NcirDNA copy number per milliliter 
of plasma.
McirDNA. A 3382-pb human ORF vector with a 786-pb MT-CO3 insert was obtained from ABM good® 
(accession no.YP_003024032) and used for the McirDNA calibration assay. Initial vector solution concentration 
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and purity were determined by measuring optic density at λ = 260 nm, 230 nm and 280 nm, with an Eppendorf 
BioPhotometer® D30. Starting vector concentration was adjusted at 1800 pg/µl for the first dilution point, accord-
ing to optic density measurement at λ = 260 nm. A qPCR standard curve was obtained by 6 successive dilutions 
of the vector solution (1800, 180, 45, 20, 10 and 5 pg/µl). The standard curve was used to determine the McirDNA 
concentration of the mCRC patients and healthy individuals and calculate the McirDNA copy number per mil-
liliter of plasma.
CirDNA copy number calculation. NcirDNA. NcirDNA copy number per milliliter of plasma, in all 
analyses, was determined with the following calculation:
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Qnuclear is the NcirDNA copy number per milliliter, c is the NcirDNA concentration (pg/µl) determined by 
qPCR targeting the nuclear KRAS gene sequence and 3.3 pg is the human haploid genome mass. Velution is the 
volume of cirDNA extract (µl) and Vplasma is the volume of plasma used for the extraction (ml).
McirDNA. McirDNA copy number per milliliter of plasma, in all analyses, was determined with the following 
calculation:
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Qmitochondrial is the McirDNA copy number per milliliter, ‘c’ is the McirDNA mass concentration (g/µl) deter-
mined by a qPCR targeting the mitochondrial MT-CO3 gene. NA is Avogadro’s number (6.02 * 1023 molecules 
per mole), Lvector is the plasmid length (nucleotides) and MW is the molecular weight of one nucleotide (g/mol). 
Velution is the elution volume of cirDNA extract (µl) and Vplasma is the volume of plasma used for the extraction 
(ml).
statistical analysis. For continuous variables, median and range were computed. To investigate their asso-
ciations with the biologic parameters, univariate statistical analyses were performed using Mann-Whitney U 
test or Kruskal-Wallis rank test for continuous variables. Moreover, multivariate analyses were carried out using 
logistic regressions, with a stepwise selection procedure, to investigate known predictive. Odds ratio (OR) with 
95% confidence intervals (CIs) are presented. The power of analysis was reduced due to all patients did not have 
measurements for all variables. All P values reported are two sided. A probability of ≤0.05 was considered to be 
statistically significant; *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001. Statistical analysis was performed 
using the STATA 13.1 software (Stata Corporation, College Station, TX).
Data Availability
The datasets used and/or analyzed during the current study are available from the corresponding author on rea-
sonable request.
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